Plasma dopamine beta hydroxylase activity in chronic schizophrenic patients tested with single dose of 2-bromo-alpha ergocriptine (Parlodel).
Plasma dopamine beta hydroxylase (D.B.H) activity was measured in 6 chronic schizophrenic patients. Treated with phenothiazine and butyrophenone derivatives after administering a single dose of bromocriptine (7,5 mg) orally, and compared to a matched group of 6 chronic treated schizophrenic patients without bromocriptine loading, and to a control matched group loaded with 7.5 mg of bromocriptine. A significant difference was observed in D.B.H. plasma levels of the schizophrenic patients group who received bromocriptine, by comparison with the other two control groups.